2025 China Antipsychotic Drugs Revenue Opportunities Report
Description
The 2025 China Antipsychotic Drugs Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antipsychotic Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the antipsychotic drugs market in China include Johnson & Johnson, Bristol Myers Squibb, Eisai (through its subsidiary EA Pharma), and Jiangsu Hengrui Pharmaceuticals. Johnson & Johnson expanded its neuroscience portfolio by acquiring Intra-Cellular Therapies, aiming to innovate in mental health treatments including schizophrenia. Bristol Myers Squibb gained FDA approval for Cobenfy, a novel antipsychotic targeting muscarinic receptors, signaling advanced therapeutic options. Eisai’s subsidiary EA Pharma licensed Newron Pharmaceuticals' modulator for schizophrenia treatment, focusing on the Asian market including China. Jiangsu Hengrui Pharmaceuticals is notable as a leading China-based pharmaceutical innovating in metabolic and psychiatric drug portfolios, supported through partnerships with venture capital ventures such as Kailera Therapeutics.
These companies are bolstered by China’s rapidly growing clinical trial environment, which surpassed the U.S. in trial volume, making China a key hub for drug development, especially for neurological and psychiatric disorders. The expanding antipsychotic drugs market in China benefits from rising awareness and prevalence of mental illness, positioning the region for the fastest growth globally in this sector. Their efforts focus on next-generation antipsychotics with novel mechanisms and formulations, such as oral films, long-acting injectables, and receptor-specific agents, aiming at improving efficacy and reducing side effects. This trend aligns with global shifts toward more patient-centric schizophrenia treatments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antipsychotic Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the antipsychotic drugs market in China include Johnson & Johnson, Bristol Myers Squibb, Eisai (through its subsidiary EA Pharma), and Jiangsu Hengrui Pharmaceuticals. Johnson & Johnson expanded its neuroscience portfolio by acquiring Intra-Cellular Therapies, aiming to innovate in mental health treatments including schizophrenia. Bristol Myers Squibb gained FDA approval for Cobenfy, a novel antipsychotic targeting muscarinic receptors, signaling advanced therapeutic options. Eisai’s subsidiary EA Pharma licensed Newron Pharmaceuticals' modulator for schizophrenia treatment, focusing on the Asian market including China. Jiangsu Hengrui Pharmaceuticals is notable as a leading China-based pharmaceutical innovating in metabolic and psychiatric drug portfolios, supported through partnerships with venture capital ventures such as Kailera Therapeutics.
These companies are bolstered by China’s rapidly growing clinical trial environment, which surpassed the U.S. in trial volume, making China a key hub for drug development, especially for neurological and psychiatric disorders. The expanding antipsychotic drugs market in China benefits from rising awareness and prevalence of mental illness, positioning the region for the fastest growth globally in this sector. Their efforts focus on next-generation antipsychotics with novel mechanisms and formulations, such as oral films, long-acting injectables, and receptor-specific agents, aiming at improving efficacy and reducing side effects. This trend aligns with global shifts toward more patient-centric schizophrenia treatments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
